You need to be logged in to see the full monograph.


Date of issue: May 2024, Version: 4

bumps logo
A corresponding patient information leaflet on USE OF GABAPENTIN IN PREGNANCY is available.

Gabapentin is an antiepileptic drug indicated as monotherapy or adjunctive therapy in the treatment of partial seizures with or without secondary generalisation, and for the treatment of peripheral neuropathic pain. It is also used off-licence for migraine prophylaxis, for the treatment of oscillopsia and spasticity in multiple sclerosis, and to ameliorate hot flushes in women receiving treatment for breast cancer.

The majority of the available epidemiological data relate to gabapentin use in pregnancy for the treatment of maternal epilepsy. A few case reports/series describe use of gabapentin in the treatment of neuropathic pain or hyperemesis gravidarum but studies have not assessed fetal outcomes following use in pregnancy for these indications. 

The available data do not provide robust evidence of an increased risk of congenital malformation overall, or for hypospadias, cleft lip, or talipes specifically, following gabapentin exposure in pregnancy. However, the evidence is also too limited to definitively exclude a risk. Data regarding risk of cardiac malformation are conflicting and likely confounded. However, the highest quality data do not indicate an increased risk. Further studies with disease-matched control groups are required.

Studies which assessed rates of miscarriage or intrauterine death following gabapentin exposure in pregnancy do not identify an increased risk of these outcomes. Conflicting results regarding a possible increased risk of preterm delivery and low birth weight have been described in a small number of studies but these data may be confounded. Data relating to neurodevelopmental impairment are limited and conflicting; therefore, further research on this subject is required before evidence-based conclusions can be drawn.

Use of any centrally acting drug throughout pregnancy or near delivery may be associated with withdrawal symptoms in the neonate and/or poor neonatal adaptation syndrome (PNAS). These symptoms are likely to be more severe in infants exposed in utero to more than one CNS acting drug. Delivery should be planned in a unit with neonatal intensive care facilities.

Gabapentin may impact upon maternal folate status. UK guidelines state that women who take any anti-epileptic medication should be prescribed high dose folic acid (5mg), although it is currently not known whether high dose folic acid supplementation offers any additional benefit or protective effects over standard dose regimes when taking gabapentin preconceptually or during pregnancy.

More research is required to define the pregnancy safety profile of gabapentin. Pregnant women and women of childbearing potential should be made aware of the lack of data for most pregnancy outcomes. Gabapentin should only be used during pregnancy where benefits of treatment are considered to outweigh any potential risks. In view of the limited human pregnancy data, close monitoring of mother and fetus should be considered with use of gabapentin in pregnancy. Other risk factors may also be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.